Advertisement

Topics

AiCuris to Pocket $122M as Merck Wins FDA Approval for New CMV Infection Drug

19:00 EST 8 Nov 2017 | BioSpace

CMV is a common and potentially serious viral infection in allogeneic HSCT recipients.

Original Article: AiCuris to Pocket $122M as Merck Wins FDA Approval for New CMV Infection Drug

NEXT ARTICLE

More From BioPortfolio on "AiCuris to Pocket $122M as Merck Wins FDA Approval for New CMV Infection Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...